These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1493 related items for PubMed ID: 18187944

  • 21. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.
    Loftus EV, Feagan BG, Colombel JF, Rubin DT, Wu EQ, Yu AP, Pollack PF, Chao J, Mulani P.
    Am J Gastroenterol; 2008 Dec; 103(12):3132-41. PubMed ID: 18853973
    [Abstract] [Full Text] [Related]

  • 22. Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre.
    Antoniou C, Stefanaki I, Stratigos A, Moustou E, Vergou T, Stavropoulos P, Avgerinou G, Rigopoulos D, Katsambas AD.
    Br J Dermatol; 2010 May; 162(5):1117-23. PubMed ID: 19906069
    [Abstract] [Full Text] [Related]

  • 23. Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139].
    Ortonne JP, Shear N, Shumack S, Henninger E, CLEAR Multinational Study Group.
    BMC Dermatol; 2005 Dec 16; 5():13. PubMed ID: 16359548
    [Abstract] [Full Text] [Related]

  • 24. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial.
    Igarashi A, Kato T, Kato M, Song M, Nakagawa H, Japanese Ustekinumab Study Group.
    J Dermatol; 2012 Mar 16; 39(3):242-52. PubMed ID: 21955098
    [Abstract] [Full Text] [Related]

  • 25. Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies.
    Armstrong AW, Reich K, Foley P, Han C, Song M, Shen YK, You Y, Papp KA.
    Am J Clin Dermatol; 2019 Feb 16; 20(1):155-164. PubMed ID: 30417277
    [Abstract] [Full Text] [Related]

  • 26. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream.
    Alora-Palli MB, Perkins AC, Van Cott A, Kimball AB.
    Am J Clin Dermatol; 2010 Feb 16; 11(4):275-83. PubMed ID: 20513160
    [Abstract] [Full Text] [Related]

  • 27. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
    Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, Li N, Gulliver W.
    Arch Dermatol; 2005 Jan 16; 141(1):31-8. PubMed ID: 15655139
    [Abstract] [Full Text] [Related]

  • 28. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).
    Barker J, Hoffmann M, Wozel G, Ortonne JP, Zheng H, van Hoogstraten H, Reich K.
    Br J Dermatol; 2011 Nov 16; 165(5):1109-17. PubMed ID: 21910713
    [Abstract] [Full Text] [Related]

  • 29. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.
    Kimball AB, Gordon KB, Fakharzadeh S, Yeilding N, Szapary PO, Schenkel B, Guzzo C, Li S, Papp KA.
    Br J Dermatol; 2012 Apr 16; 166(4):861-72. PubMed ID: 22356258
    [Abstract] [Full Text] [Related]

  • 30. Demographic characteristics and health-related quality of life of patients with moderate-to-severe psoriasis: The VACAP study.
    Daudén E, Pujol RM, Sánchez-Carazo JL, Toribio J, Vanaclocha F, Puig L, Yébenes M, Sabater E, Casado MA, Caloto MT, Aragón B, VACAP Study Investigators.
    Actas Dermosifiliogr; 2013 Nov 16; 104(9):807-14. PubMed ID: 23827342
    [Abstract] [Full Text] [Related]

  • 31. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients.
    Abrouk M, Nakamura M, Zhu TH, Farahnik B, Koo J, Bhutani T.
    J Dermatolog Treat; 2017 Sep 16; 28(6):488-491. PubMed ID: 28042711
    [Abstract] [Full Text] [Related]

  • 32. Psoriasis affects patient's quality of life more seriously in female than in male in Japan.
    Mabuchi T, Yamaoka H, Kojima T, Ikoma N, Akasaka E, Ozawa A.
    Tokai J Exp Clin Med; 2012 Sep 20; 37(3):84-8. PubMed ID: 23032250
    [Abstract] [Full Text] [Related]

  • 33. Efficacy of adalimumab in the treatment of psoriasis: a retrospective study of 15 patients in daily practice.
    Sola-Ortigosa J, Sánchez-Regaña M, Umbert-Millet P.
    J Dermatolog Treat; 2012 Jun 20; 23(3):203-7. PubMed ID: 21787203
    [Abstract] [Full Text] [Related]

  • 34. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial.
    Torii H, Nakagawa H, Japanese Infliximab Study investigators.
    J Dermatol Sci; 2010 Jul 20; 59(1):40-9. PubMed ID: 20547039
    [Abstract] [Full Text] [Related]

  • 35. Impact of active and stable psoriasis on health-related quality of life: the PSO-LIFE study.
    Daudén E, Herrera E, Puig L, Sánchez-Carazo JL, Toribio J, Perulero N.
    Actas Dermosifiliogr; 2013 Oct 20; 104(8):685-93. PubMed ID: 23958428
    [Abstract] [Full Text] [Related]

  • 36. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis.
    Menter A, Gordon KB, Leonardi CL, Gu Y, Goldblum OM.
    J Am Acad Dermatol; 2010 Sep 20; 63(3):448-56. PubMed ID: 20605254
    [Abstract] [Full Text] [Related]

  • 37. Infliximab for the treatment of adults with psoriasis.
    Loveman E, Turner D, Hartwell D, Cooper K, Clegg A.
    Health Technol Assess; 2009 Jun 20; 13 Suppl 1():55-60. PubMed ID: 19567215
    [Abstract] [Full Text] [Related]

  • 38. Switch to biological agent in psoriasis significantly improved clinical and patient-reported outcomes in real-world practice.
    Norlin JM, Steen Carlsson K, Persson U, Schmitt-Egenolf M.
    Dermatology; 2012 Jun 20; 225(4):326-32. PubMed ID: 23328678
    [Abstract] [Full Text] [Related]

  • 39. Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis.
    Kavanaugh A, Antoni C, Krueger GG, Yan S, Bala M, Dooley LT, Beutler A, Guzzo C, Gladman D.
    Ann Rheum Dis; 2006 Apr 20; 65(4):471-7. PubMed ID: 16096330
    [Abstract] [Full Text] [Related]

  • 40. Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab.
    Elewski BE, Puig L, Mordin M, Gilloteau I, Sherif B, Fox T, Gnanasakthy A, Papavassilis C, Strober BE.
    J Dermatolog Treat; 2017 Sep 20; 28(6):492-499. PubMed ID: 28266243
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 75.